Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

被引：3

作者：

Gumus, Mahmut

Chen, Chieh-I

Ivanescu, Cristina

Kilickap, Saadettin

Bondarenko, Igor

Ozguroglu, Mustafa

Gogishvili, Miranda

Turk, Haci M.

Cicin, Irfan

Harnett, James

Mastey, Vera

Naumann, Ulrike

Reaney, Matthew

Konidaris, Gerasimos

Sasane, Medha

Brady, Keri

Li, Siyu

Gullo, Giuseppe

Rietschel, Petra

Sezer, Ahmet

机构：

[1] Istanbul Medeniyet Univ, Istanbul, Turkey

[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[3] IQVIA, Durham, NC USA

[4] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey

[5] Dnipropetrovsk State Med Acad, City Multifield Clin Hosp, Dnepropetrovsk, Ukraine

[6] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey

[7] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia

[8] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[9] Trakya Univ, Dept Med Oncol, Edirne, Turkey

[10] Sanofi, Reading, Berks, England

[11] Sanofi, Bridgewater, NJ USA

[12] Sanofi, Cambridge, MA USA

[13] Baskent Univ, Dept Med Oncol, Adana, Turkey

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9078

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9078

引用

页数：3

共 50 条

[41] Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
Tambo, Yuichi
Sone, Takashi
Shibata, Kazuhiko
Nishi, Kouichi
Shirasaki, Hiroki
Yoneda, Taro
Araya, Tomoyuki
Kase, Kazumasa
Nishikawa, Shingo
Kimura, Hideharu
Kasahara, Kazuo
ANNALS OF ONCOLOGY, 2021, 32 : S313 - S313
[42] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
Velcheti, Vamsidhar
Hu, Xiaohan
Li, Yeran
El-Osta, Hazem
Pietanza, M. Catherine
Burke, Thomas
CANCERS, 2022, 14 (04)
[43] Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1-Selected Patients With Advanced NSCLC
Carcereny, E.
Felip, E.
Reck, M.
Patel, J.
Heist, R.
Balmanoukian, A.
Chow, L.
Paz-Ares, L.
Qiu, J.
Coleman, S.
Mocci, S.
Sandler, A.
Kurata, T.
Shepherd, F.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1792
[44] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
Wu, Y.
Zhang, L.
Fan, Y.
Zhou, J.
Zhang, L.
Zhou, Q.
Li, W.
Hu, C.
Chen, G.
Zhang, X.
Zhou, C.
Dang, T.
Penrod, J.
Kush, D.
Qin, Y.
Li, B.
Mok, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
[45] First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
Ren, Shengxiang
Wang, Xicheng
Han, Bao-Hui
Pan, Yueyin
Zhao, Jun
Cheng, Yufeng
Hu, Sheng
Liu, Tianshu
Li, Yalun
Cheng, Ying
Feng, Jifeng
Yi, Shanyong
Gu, Shanzhi
Gao, Shegan
Luo, Yongzhong
Liu, Ying
Liu, Caigang
Duan, Huijie
Wang, Shuni
Yang, Xinfeng
Fan, Jia
Zhou, Caicun
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
[46] PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 < 50%: a multiomics analysis
Lo Russo, Giuseppe
Prelaj, Arsela
Dolezal, James
Beninato, Teresa
Agnelli, Luca
Triulzi, Tiziana
Fabbri, Alessandra
Lorenzini, Daniele
Ferrara, Roberto
Brambilla, Marta
Occhipinti, Mario
Mazzeo, Laura
Provenzano, Leonardo
Spagnoletti, Andrea
Viscardi, Giuseppe
Sgambelluri, Francesco
Brich, Silvia
Miskovic, Vanja
Pedrocchi, Alessandra Laura Giulia
Trovo, Francesco
Manglaviti, Sara
Giani, Claudia
Ambrosini, Paolo
Leporati, Rita
Franza, Andrea
McCulloch, John
Torelli, Tommaso
Anichini, Andrea
Mortarini, Roberta
Trinchieri, Giorgio
Pruneri, Giancarlo
Torri, Valter
De Braud, Filippo
Proto, Claudia
Ganzinelli, Monica
Garassino, Marina Chiara
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
[47] Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.
Kuznik, Andreas
Smare, Caitlin
Chen, Chieh-I
Venkatachalam, Meena
Keeping, Sam
Atsou, Kokuvi
Xu, Yingxin
Wilson, Florence
Guyot, Patricia
Chan, Keith
Glowienka, Emily
Konidaris, Gerasimos
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[48] PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
Garcia Campelo, Maria Rosario
Arriola, Edurne
Campos Balea, Begona
Lopez-Brea, Marta
Fuentes-Pradera, Jose
de Castro Carpeno, Javier
Aguado, Carlos
Perez Parente, Diego
de Oro Pulido, Fidel
Ruiz-Gracia, Pedro
Rodriguez-Abreu, Delvys
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
[49] PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
Garcia Campelo, M. R.
Arriola Aperribay, E.
Campos Balea, B.
Lopez-Brea, M.
Fuentes Pradera, J.
de Castro Carpeno, J.
Aguado, C.
Perez Parente, D.
de Oro-Pulido, F.
Rodriguez Abreu, D.
ANNALS OF ONCOLOGY, 2021, 32 : S1413 - S1414
[50] IMPACT OF CRIZOTINIB TREATMENT ON PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) IN ASIAN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Shi, Yuankai
Iyer, S.
Kim, Dong-wan
Reisman, A.
Liu, Xiaoquing
Nakagawa, K.
Yang, P.
Ahn, M-J
Milner, Keith
Hida, Toyoaki
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S491 - S491

← 1 2 3 4 5 →